主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察

Curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis

目的:研究主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液的效果及对患者预后的影响。方法:选择卵巢癌伴腹腔积液患者90例,按随机数表法分为对照组及观察组。对照组采用常规静脉化疗治疗,观察组在对照组基础上采用主动循环腹腔热灌注化疗治疗,两组患者均治疗6个疗程并随访1年。统计两组患者肿瘤及腹腔积液疗效、1年生存率、化疗不良反应发生率,检测并比较治疗前后腹水中血管内皮生长因子(VEGF)、癌抗原(CA 125)、人附睾蛋白4(HE-4)水平。结果:观察组肿瘤治疗疾病控制率(82.22%)高于对照组(62.22%)(P<0.05);观察组腹腔积水治疗有效率、疾病控制率(73.33%、95.56%)均高于对照组(51.11%、77.78%)(P<0.05);观察组治疗后VEGF、CA 125、HE-4水平均低于对照组(P<0.05);观察组1年生存率为86.67%(39/45)高于对照组66.67%(30/45)(P<0.05);两组患者化疗不良反应发生率无统计学差异(P>0.05)。结论:主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液可提升治疗效果,并降低肿瘤标志物水平。

Objective:To study the curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis.Methods:Selection of 90 patients with ovarian cancer and ascites.They were divided into control group and observation group according to random number table method.The control group was given routine intravenous chemotherapy.On this basis,observation group was given active circulation intraperitoneal hyperthermic perfusion chemotherapy.Both groups were treated for 6 courses and followed up for 1 year.The curative effect of tumor and seroperitoneum,1-year survival rate,incidence of side effects by chemotherapy in both groups were statistically analyzed.The levels of vascular endothelial growth factor(VEGF),cancer antigen(CA125) and human epididymis protein 4(HE-4)in ascites before and after treatment were measured.Results:The disease control rate of tumor treatment in observation group was higher than that in control group(82.22% vs 62.22%)(P<0.05).The response rate of seroperitoneum treatment and disease control rate(73.33%,95.56%) in observation group were higher than those in control group(51.11%,77.78%)(P<0.05).After treatment,VEGF,CA125 and HE-4 levels in observation group were lower than those in control group(P<0.05).The 1-year survival rate of observation group was higher than that of control group[86.67%(39/45) vs 66.67%(30/45)](P<0.05).There was no significant difference in incidence of side effects by chemotherapy between the two groups(P>0.05).Conclusion:Active circulation intraperitoneal hyperthermic perfusion chemotherapy in treatment of ovarian cancer combined with seroperitoneum can improve curative effect and reduce levels of tumor markers.